Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
1093results about "NGF-receptor/TNF-receptor superfamily" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Mammalian cell surface antigens; related reagents
InactiveUS7025962B1Abnormal immune responseFacilitated DiffusionPeptide/protein ingredientsAntibody mimetics/scaffoldsMammalT cell
Owner:MERCK SHARP & DOHME CORP
Chimeric receptors with 4-1BB stimulatory signaling domain
InactiveUS20050113564A1Antibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsNatural Killer Cell Inhibitory ReceptorsT cell
The present invention relates to a chimeric receptor capable of signaling both a primary and a co-stimulatory pathway, thus allowing activation of the co-stimulatory pathway without binding to the natural ligand. The cytoplasmic domain of the receptor contains a portion of the 4-1BB signaling domain. Embodiments of the invention relate to polynucleotides that encode the receptor, vectors and host cells encoding a chimeric receptor, particularly including T cells and natural killer (NK) cells and methods of use. Also included is a method for obtaining an enriched population of NK cells from a mixed population of NK cells and T cells.
Owner:ST JUDE CHILDRENS RES HOSPITAL INC
Chimeric antigen receptor
ActiveUS20140242701A1High expressionHigh cytotoxic activityAntibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsAntigenAntigen receptor
Provided are a chimeric antigen receptor comprising an extracellular domain capable of binding to an antigen, a transmembrane domain and at least one intracellular domain, the chimeric antigen receptor being characterized in that an intracellular domain of a glucocorticoid-induced tumor necrosis factor receptor (GITR) is contained as the intracellular domain; a nucleic acid encoding the chimeric antigen receptor; a cell expressing the chimeric antigen receptor; and a method for producing the cell.
Owner:MIE UNIVERSITY
Modified cell line and method for expansion of NK cell
ActiveUS7435596B2Highly efficient transductionBiocideGenetic material ingredientsCD137Natural Killer Cell Inhibitory Receptors
The present invention relates to novel methods for preferentially activating and expanding NK cells. The methods utilize the stimulatory effects of IL-15 and CD137 ligand to preferentially expand and activate NK cells in a mixed cell culture comprising NK cells.
Owner:ST JUDE CHILDRENS RES HOSPITAL INC
Bispecific chimeric antigen receptors and therapeutic uses thereof
ActiveUS20150038684A1Peptide/protein ingredientsAntibody mimetics/scaffoldsIntracellular signallingAntigen receptors
The invention is directed to a bispecific chimeric antigen receptor, comprising: (a) at least two antigen-specific targeting regions; (b) an extracellular spacer domain; (c) a transmembrane domain; (d) at least one co-stimulatory domain; and (e) an intracellular signaling domain, wherein each antigen-specific targeting region comprises an antigen-specific single chain Fv (scFv) fragment, and binds a different antigen, and wherein the bispecific chimeric antigen receptor is co-expressed with a therapeutic control. The invention also provides methods and uses of the bispecific chimeric antigen receptors.
Owner:SEATTLE CHILDRENS HOSPITAL
Chimeric antigen receptors targeting b-cell maturation antigen
ActiveUS20150051266A1Antibody mimetics/scaffoldsGenetic material ingredientsAntigenAntigen receptors
The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
Owner:UNITED STATES OF AMERICA
Reducing the immunogenicity of fusion proteins
InactiveUS6992174B2Low immunogenicityHigh expressionPeptide/protein ingredientsAntibody mimetics/scaffoldsMHC class IIVaccine Immunogenicity
Disclosed are compositions and methods for producing fusion proteins with reduced immunogenicity. Fusion proteins of the invention include a junction region having an amino acid change that reduces the ability of a junctional epitope to bind to MHC Class II, thereby reducing its interaction with a T-cell receptor. Methods of the invention involve analyzing, changing, or modifying one or more amino acids in the junction region of a fusion protein in order to identify a T-cell epitope and reduce its ability to interact with a T cell receptor. Compositions and methods of the invention are useful in therapy.
Owner:MERCK PATENT GMBH
Compositions and Methods for Targeted Immunomodulatory Antibodies and Fusion Proteins
ActiveUS20130039911A1Function increaseOrganic active ingredientsPeptide/protein ingredientsTumor targetAntitumor immunity
The present invention is based on the seminal discovery that targeted immunomodulatory antobodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are able to escape elimination by chemotherapeutic agents or tumor-targeted antobodies via specific immunosuppressive mechanisms in the tumor microenvironment and such ability of cancer cells is recognized as immune tolerance. Such immuno-suppressive mechanisms include immunosuppressive cytokines (for example, Transforming growth factor beta (TGF-β)) and regulatory T cells and / or immunosuppressive myeloid dendritic cells (DCs). By conteracting tumor-induced immune tolerance, the present invention provides effective compositions and methods for cancer treatment, optional in combination with another existing cancer treatment. The present invention provides strategies to counteract tumor-induced immune tolerance and enhance the antitumor efficacy of chemotherapy by activating and leveraging T cell-mediated adaptive antitumor immunity against resistant or disseminated cancer cells.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Chimeric antigen receptors targeting B-cell maturation antigen
ActiveUS9765342B2Polypeptide with localisation/targeting motifImmunoglobulin superfamilyAntigenAntigen receptors
The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
Owner:UNITED STATES OF AMERICA
Soluble tumor necrosis factor receptor treatment of medical disorders
The invention pertains to methods and compositions for treating medical disorders characterized by elevated levels or abnormal expression of TNFα by administering a TNFα antagonist, such as recombinant TNFR:Fc.
Owner:IMMUNEX CORP
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
ActiveUS8993524B2Function increaseOrganic active ingredientsPeptide/protein ingredientsTumor targetAntitumor immunity
The present invention is based on the seminal discovery that targeted immunomodulatory antibodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are able to escape elimination by chemotherapeutic agents or tumor-targeted antibodies via specific immunosuppressive mechanisms in the tumor microenvironment and such ability of cancer cells is recognized as immune tolerance. Such immune suppressive mechanisms include immunosuppressive cytokines (for example, Transforming growth factor beta (TGF-β) and regulatory T cells and / or immunosuppressive myeloid dendritic cells (DCs). By counteracting tumor-induced immune tolerance, the present invention provides effective compositions and methods for cancer treatment, optional in combination with another existing cancer treatment. The present invention provides strategies to counteract tumor-induced immune tolerance and enhance the antitumor efficacy of chemotherapy by activating and leveraging T cell-mediated adaptive antitumor immunity against resistant or disseminated cancer cells.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Expansion of NK cells and therapeutic uses thereof
ActiveUS20060093605A1Highly efficient transductionImmunoglobulin superfamilyGenetically modified cellsCD137Natural Killer Cell Inhibitory Receptors
The present invention relates to novel methods for preferentially activating and expanding NK cells. The methods utilize the stimulatory effects of IL-15 and CD137 ligand to preferentially expand and activate NK cells in a mixed cell culture comprising NK cells.
Owner:ST JUDE CHILDRENS RES HOSPITAL INC
Bispecific chimeric antigen receptors and encoding polynucleotides thereof
ActiveUS9447194B2Peptide/protein ingredientsAntibody mimetics/scaffoldsIntracellularAntigen receptors
The invention is directed to a bispecific chimeric antigen receptor, comprising: (a) at least two antigen-specific targeting regions; (b) an extracellular spacer domain; (c) a transmembrane domain; (d) at least one co-stimulatory domain; and (e) an intracellular signaling domain, wherein each antigen-specific targeting region comprises an antigen-specific single chain Fv (scFv) fragment, and binds a different antigen, and wherein the bispecific chimeric antigen receptor is co-expressed with a therapeutic control. The invention also provides methods and uses of the bispecific chimeric antigen receptors.
Owner:SEATTLE CHILDRENS HOSPITAL
Death domain containing receptor 5
The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding the human DR5 proteins. DR5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying antagonists and antagonists of DR5 activity. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR5, which maybe agonists and / or antagonists of DR5 activity.
Owner:HUMAN GENOME SCI INC
Chimeric proteins and methods for using the same
InactiveUS7569663B2Enhanced advantageImprove propertiesCompounds screening/testingPeptide/protein ingredientsTrans signalingDisease
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Methods of protein production using Anti-senescence compounds
PendingUS20080274507A1High protein yieldIncrease productionGenetically modified cellsCulture processBiotechnologyAntioxidant
Owner:WYETH LLC
CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF
ActiveUS20180187149A1Reduce in quantityPolypeptide with localisation/targeting motifImmunoglobulin superfamilyAntigen receptorsCAR - Chimeric antigen receptor
The present invention relates to compositions and methods relating to chimeric antigen receptor (CAR) polypeptides and methods relating thereto. In one embodiment, the present invention relates to engineered cells having chimeric antigen receptor polypeptides directed to at least two targets. In another embodiment, the present invention relates to engineered cells having chimeric antigen receptor polypeptides and an enhancer moiety.
Owner:ICELL GENE THERAPEUTICS LLC
Mnd promoter chimeric antigen receptors
ActiveUS20170051308A1Antibody mimetics/scaffoldsGenetic material ingredientsBinding siteAntigen receptors
Vector compositions comprising a myeloproliferative sarcoma virus enhancer, negative control region deleted, dl587rev primer-binding site substituted (MND) promoter operably linked to a chimeric antigen receptor (CAR) are provided.
Owner:2SEVENTY BIO INC
Bcma (CD269) specific chimeric antigen receptors for cancer immunotherapy
ActiveUS20170183418A1Useful for immunotherapyHigh selectivityAntibody mimetics/scaffoldsNGF/TNF-superfamilyAntigenSpecific immunity
The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a BCMA monoclonal antibody, conferring specific immunity against BCMA positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas, multiple myeloma and leukemia.
Owner:CELLECTIS SA
Inhibiting B cell activation with soluble CD40 or fusion proteins thereof
The present invention relates to a counter-receptor, termed CD40CR, for the CD40 B-cell antigen, and to soluble ligands for this receptor, including fusion molecules comprising at least a portion of CD40 protein. It is based, at least in part, on the discovery that a soluble CD40 / immunoglobulin fusion protein or antibody specific for gp39 on T cells was able to inhibit helper T-cell mediated B-cell activation by binding to a novel 39 kD protein receptor on helper T-cell membranes. The present invention provides for a substantially purified CD40CR receptor; for soluble ligands of CD40CR, including antibodies as well as fusion molecules comprising at least a portion of CD40 protein; and for methods of controlling B-cell activation which may be especially useful in the treatment of allergy or autoimmune disease, including graft-versus-host disease and rheumatoid arthritis.
Owner:BRISTOL MYERS SQUIBB CO +1
Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses
InactiveUS6265535B1Improve structural stabilityInhibit bindingNGF-receptor/TNF-receptor superfamilyCyclic peptide ingredientsCyclic peptideBinding site
Owner:PENNSYLVANIA UNIV TRUSTEES OF THE
Inhibitor which is deactivatable by a reagent produced by a target cell
ActiveUS8809504B2Undesirable effectModulating responseNGF/TNF-superfamilyAntibody ingredientsActive agentWhole body
The invention relates to molecules inhibiting biologically active compounds and further comprising moieties specifically cleavable by a reagent produced by a target cell. The invention relates to inhibitors that bind, inhibit, suppress, neutralize, or decrease activity of a biologically active agent. Inhibitors comprise at least one moiety that bind, inhibit, suppress, neutralize, or decrease activity of a biologically active agent and at least one moiety that can be cleaved specifically by a reagent produced by target cells. The cleavage deactivates the inhibitor. Following cleavage, the active agent is liberated into the local environment. Administration of the inhibitor alone or together with the active agent suppress the compound's activity until it reaches the proximity of a target cell. Targeted specific release enables the agent concentration in specific site to reach levels that have desired therapeutic effects without systemic toxicity.
Owner:VYTACERA BIO LLC
Compositions and methods for immunotherapy
ActiveUS20160045551A1High activityAntibacterial agentsImmunological disordersAntigen receptorAntigen
The present invention provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to immunoresponsive cells bearing antigen receptors, which can be chimeric antigen receptors (CARS), which express introduced ligands for immunomodulatory molecules. In particular embodiments, engineered immunoresponsive cells are antigen-directed and resist immunosuppression and / or have enhances immune-activating properties.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT
Use of low temperature and/or low ph in cell culture
ActiveUS20080269132A1Reduce productionReduce the temperaturePeptide/protein ingredientsGenetically modified cellsCulture cellTherapeutic protein
The present invention provides a novel method of reducing protein misfolding and aggregation in the cell culture by growing the cell culture at a reduced temperature and / or reduced pH. As a result, the quality of the protein produced in the cell culture is greatly improved. Thus, the present invention facilitates improvements in the efficacy of therapeutic proteins produced in cell culture.
Owner:WYETH LLC
Subset-optimized chimeric antigen receptor-containing t-cells
PendingUS20170209492A1Improve anti-tumor activityIncreased persistenceOrganic active ingredientsAntibody mimetics/scaffoldsDiseaseIntracellular signalling
This disclosure provides, for instance subset-optimized CART cells and related methods. For instance, the disclosure describes methods and compositions of CD4′ and CD8′ T cells that express CARs containing specific combinations of intracellular signaling domains can be used to increase persistence and anti-tumor activity of the infused CAR-expressing T cells for treating a subject having a disease, e.g., a cancer.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA +1
Monoclonal antibodies that bind OCIF
InactiveUS6919434B1Efficient productionMicrobiological testing/measurementEnzymologyADAMTS ProteinsEmbryo
A protein which inhibits osteoclast diffraction and / or maturation and a method for producing the protein. The protein is produced by human embryonic lung fibroblasts and has a molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions an SDS-polyacrylamide gel electrophoresis. The protein can be isolated and purified from the culture medium of fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity for the protein or a method for determining protein concentration using these antibodies.
Owner:DAIICHI SANKYO CO LTD
Anti-cd40 antibodies and uses thereof
ActiveUS20140093497A1Reduce the frequency of occurrenceReduce severityOrganic active ingredientsMicroorganismsEpitopeTransplant rejection
The present invention relates to antibodies specific for a particular epitope on CD40 and antibodies that bind CD40 and have particular functional characteristics. The present invention also relates to fragments of these antibodies, uses of the antibodies for reduction or treatment of transplant rejection and graft-versus-host disease, and methods for making the antibodies.
Owner:EMORY UNIVERSITY +1
Novel chimeric proteins and methods for using the same
InactiveUS20030216546A1Compounds screening/testingPeptide/protein ingredientsDiseaseProtein insertion
Novel chimeric proteins are disclosed. The proteins comprise at least two portions. The first portion binds to a first cell and decreases the cell's ability to send a trans signal to a second cell; the second portion sends its own trans signal to the second cell. Methods for making and using these proteins in the treatment of cancer, viral infections, autoimmune and alloimmune diseases are also disclosed, as are pharmaceutical formulations comprising the novel chimeric proteins and genes. Either the proteins themselves or a genetic sequence encoding the protein can be administered. Other methods are also disclosed in which two molecular components result in decrement of a first trans signal from a first cell and the conferring of a second trans signal to a second cell.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Death domain containing receptor 5
The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding the human DR5 proteins. DR5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying antagonists and antagonists of DR5 activity. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR5, which may be agonists and / or antagonists of DR5 activity.
Owner:HUMAN GENOME SCI INC
Biomarkers predictive of cytokine release syndrome
ActiveUS20180252727A1Reduce riskHigh activityOrganic active ingredientsAntipyreticAnalyteProtein expression profile
Owner:NOVARTIS AG +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com